Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Magnesium Isoglycyrrhizinate API market size was valued at USD 38.2 million in 2025. The market is projected to grow from USD 40.6 million in 2026 to USD 58.4 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period. The U.S. market was estimated at USD 6.5 million in 2025, while Chinas market, a dominant regional force, is projected to reach USD 22.8 million by 2032.
Magnesium Isoglycyrrhizinate is an active pharmaceutical ingredient (API) derived from glycyrrhizin, a compound extracted from licorice root. It is chemically defined as the magnesium salt of 18-glycyrrhizic acid and is recognized for its potent hepatoprotective, anti-inflammatory, and anti-viral properties. Primarily, this API is a crucial component in injectable formulations for treating chronic hepatitis and liver diseases, particularly in the Asia-Pacific region. Its mechanism involves stabilizing liver cell membranes and inhibiting inflammatory mediators, making it a therapeutic mainstay in hepatology.
The market growth is fueled by the increasing global prevalence of liver diseases, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and drug-induced liver injury. Furthermore, the rising demand for natural and plant-derived APIs in pharmaceutical formulations supports market expansion. However, the market faces challenges, including stringent regulatory requirements for API approval and competition from alternative hepatoprotective agents. The competitive landscape is characterized by several key manufacturers from China, which is the production and consumption hub. Major players like Lianyungang Runzhong Pharmaceutical, Nanjing hongshenghuo Biotechnology, Alikang Pharmaceutical, and Wuhan Weisman Bioengineering collectively hold a significant revenue share, driving innovation and supply in this specialized market segment.
Rising Global Burden of Liver Diseases
The increasing global prevalence of chronic liver conditions, including drug-induced liver injury, non-alcoholic fatty liver disease (NAFLD), and hepatitis, is a primary driver for the Magnesium Isoglycyrrhizinate API market. This compound is a key active ingredient in hepatoprotective drugs, leading to sustained demand from pharmaceutical formulation manufacturers.
Growth of the Pharmaceutical Sector in Asia-Pacific
The expansion of the pharmaceutical industry, particularly in China where Magnesium Isoglycyrrhizinate was developed, is a significant market force. Increased manufacturing capacity, coupled with growing exports of finished formulations containing this API, is propelling market growth. Government support for domestic API production further strengthens this driver.
Recognition of its superior safety profile compared to older glycyrrhizin derivatives is leading to its inclusion in more formularies and treatment guidelines.
Ongoing research into the anti-inflammatory and antiviral mechanisms of Magnesium Isoglycyrrhizinate is opening potential avenues for new therapeutic applications beyond hepatoprotection, which stimulates R&D investment and long-term market interest.
MARKET CHALLENGES
Regulatory Hurdles in Western Markets
While well-established in several Asian pharmacopoeias, Magnesium Isoglycyrrhizinate faces significant regulatory challenges in Western markets like the US and EU. The requirement for extensive new clinical trials to gain approval as a new chemical entity involves high costs and long timelines, limiting its market penetration globally.
Other Challenges
Supply Chain Dependency on Limited Sources
The production of the API is heavily reliant on the cultivation and sustainable sourcing of licorice root (Glycyrrhiza species). Fluctuations in agricultural yield, quality consistency, and geopolitical factors affecting raw material trade present persistent supply chain challenges for manufacturers.
Price Sensitivity and Competition
The market faces pressure from alternative hepatoprotective agents and generic competition, which creates price sensitivity. Manufacturers must balance production costs, which are influenced by the extraction and purification processes, against competitive pricing to maintain market share.
Limited Robust Clinical Evidence by International Standards
A key factor restraining broader global adoption is the perception that the existing body of clinical evidence, while substantial in certain regions, may not fully meet the stringent efficacy and trial design criteria demanded by major international regulatory agencies. This creates a barrier to entry in high-value markets.
Stringent Good Manufacturing Practice (GMP) Compliance Costs
Adhering to the increasingly strict GMP standards required for API production, especially for export to regulated markets, necessitates significant capital investment in facility upgrades, quality control systems, and personnel training. These high compliance costs can be a restraint, particularly for smaller producers.
Expansion into Emerging Pharmaceutical Markets
There is significant opportunity for growth in emerging markets across Latin America, the Middle East, and Africa, where regulatory pathways may be more receptive and the burden of liver disease is rising. Tailoring regulatory submissions and partnering with local distributors in these regions can unlock new demand.
Development of Combination Therapies and New Formulations
Innovation in drug delivery and formulation presents a key opportunity. Developing fixed-dose combination drugs that pair Magnesium Isoglycyrrhizinate with other hepatoprotective or antiviral agents, or creating novel formulations like sustained-release tablets, can enhance therapeutic value and create new, patent-protected products.
Strategic Partnerships for Clinical Development
Forming strategic alliances with global contract research organizations (CROs) and pharmaceutical companies to conduct high-quality, international-standard clinical trials is a major opportunity. Successfully demonstrating efficacy in new indications can dramatically expand the approved use and market scope of the API.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Purity 98% stands as the dominant segment due to its superior efficacy and compatibility for pharmaceutical-grade formulations. The demand for high-purity API is driven by stringent regulatory standards in drug manufacturing and a growing preference for premium active ingredients in both therapeutics and high-end skincare products. This segment benefits from a perception of higher safety and more consistent therapeutic outcomes, making it the preferred choice for manufacturers aiming to differentiate their offerings in competitive markets, particularly for injectable and systemic treatments. |
| By Application |
|
Pharmaceuticals represents the most significant application segment, fueled by the API's established anti-inflammatory and hepatoprotective properties used in treating skin conditions like eczema and psoriasis. The segment's growth is further underpinned by ongoing clinical research exploring its therapeutic potential in broader inflammatory disorders. Concurrently, the Cosmetics and Skin Care application is experiencing rapid growth, driven by the rising consumer demand for bioactive, natural-origin ingredients in anti-aging, soothing, and brightening formulations, creating a dual demand stream from both therapeutic and cosmetic innovation. |
| By End User |
|
Pharmaceutical Manufacturers are the primary end users, leveraging the API for formulation development of prescription and over-the-counter dermatological drugs. Their demand is characterized by a focus on consistent quality, supply chain reliability, and regulatory compliance. Cosmetic & Skincare Brands represent a dynamic and growing end-user segment, increasingly integrating the ingredient into serums, creams, and targeted treatments to capitalize on the "cosmeceutical" trend. Additionally, Contract Manufacturing Organizations are becoming important consumers as brand owners outsource production to specialized facilities with formulation expertise. |
| By Manufacturing Process |
|
Extraction & Purification is the leading process segment, as the compound is primarily derived from licorice root, aligning with the market's demand for natural and plant-based actives. Advances in purification technologies are crucial for improving yield and achieving the high-purity grades demanded by pharmaceutical applications. The focus within this segment is on sustainable sourcing, optimization of extraction efficiency, and minimizing environmental impact, which are key competitive factors for API suppliers like Lianyungang Runzhong Pharmaceutical and Nanjing hongshenghuo Biotechnology. |
| By Supply Chain Role |
|
Direct Suppliers/Manufacturers hold a commanding position, as the market is characterized by specialized production concentrated among key players in regions like Asia. These entities, including Alikang Pharmaceutical and Wuhan Weisman Bioengineering, control the core technology and quality standards, giving them significant influence over pricing and availability. Their role is expanding as they engage more directly with end-users for custom synthesis and collaborative R&D. Distributors play a vital role in ensuring global market access, particularly for smaller cosmetic brands and research institutions seeking smaller batch quantities. |
Market Dominated by Specialized Chinese Manufacturers with Global Reach
The global Magnesium Isoglycyrrhizinate API market is characterized by a moderately consolidated competitive structure, with the top five players accounting for a significant revenue share. Leadership is concentrated among a select group of specialized Chinese manufacturers that combine expertise in botanical extraction and pharmaceutical-grade synthesis. Lianyungang Runzhong Pharmaceutical is recognized as a prominent player, often leading in terms of production scale and revenue, with a strong focus on supplying high-purity (98%) API for pharmaceutical applications. Close competitors like Nanjing hongshenghuo Biotechnology and Alikang Pharmaceutical reinforce this dynamic, leveraging robust R&D and vertically integrated supply chains from licorice root sourcing to finished API. This core group competes intensely on quality certifications, production efficiency, and strategic partnerships with major pharmaceutical and cosmeceutical formulators globally.
The competitive field extends to several other established and emerging manufacturers that serve niche segments and regional markets. Companies such as Wuhan Weisman Bioengineering have carved out significant positions by specializing in advanced purification technologies. Beyond these, a cadre of other suppliers competes by offering competitive pricing, flexibility in order volume, or by catering to the growing demand in the cosmetics and skincare segment, which requires stringent but slightly different quality parameters than pharmaceutical applications. The market's growth is further fueled by manufacturers expanding their footprint in Europe and North America through distribution agreements, though production remains largely centered in the Asia-Pacific region, particularly China, due to raw material access and manufacturing expertise.
List of Key Magnesium Isoglycyrrhizinate API Companies ProfiledAlikang Pharmaceutical Co., Ltd.
Chengdu Biopurify Phytochemicals Ltd.
Shaanxi Huike Botanical Development Co., Ltd.
Xi'an Natural Field Bio-Technique Co., Ltd.
Nanjing Zelang Medical Technology Co., Ltd.
Hangzhou Hyper Chemicals Limited
ChemFaces Biochemical Co., Ltd.
Shanghai Tauto Biotech Co., Ltd.
Jiangsu Yongjian Pharmaceutical Co., Ltd.
Hunan Kangshou Pharmaceutical Co., Ltd.
The global Magnesium Isoglycyrrhizinate API market is on a robust growth trajectory, projected to expand at a significant compound annual growth rate from 2025 to 2032. This growth is fundamentally driven by the well-documented anti-inflammatory and hepatoprotective properties of the compound, which is a magnesium salt derived from glycyrrhizin found in licorice root. The rising prevalence of skin conditions such as eczema and psoriasis, coupled with increasing consumer demand for scientifically-backed active ingredients in both pharmaceuticals and advanced skincare, is fueling sustained demand. The market saw a valuation in the millions in 2025, with projections indicating a rise to several hundred million US dollars by the end of the forecast period, underscoring the strong commercial interest and clinical validation of this API.
Other TrendsHigh-Purity Segment as a Key Revenue Driver
The Purity98% segment is a standout performer, expected to reach several million dollars by 2032 with a high CAGR over the subsequent six years. This trend reflects the pharmaceutical industry's stringent quality requirements and a consumer shift toward premium, high-efficacy formulations in the cosmetics sector. Manufacturers are focusing on advanced purification technologies to cater to this high-value segment, which commands a larger revenue share.
The global market features a concentrated competitive landscape, with the top five players, including Lianyungang Runzhong Pharmaceutical, Nanjing hongshenghuo Biotechnology, Alikang Pharmaceutical, and Wuhan Weisman Bioengineering, accounting for a significant share of total revenue as of 2025. Geographically, Asia, led by China, represents the largest and fastest-growing regional market, driven by local manufacturing prowess and high domestic consumption. North America, particularly the U.S., holds a substantial market size valued in the millions, representing a major center for advanced pharmaceutical and cosmetic formulation development. This regional diversification highlights the global acceptance and application of Magnesium Isoglycyrrhizinate API across key therapeutic and consumer markets.
Regional Analysis: Magnesium Isoglycyrrhizinate API MarketNorth America
North America represents a significant and technologically advanced market, characterized by a strong focus on high-quality, clinically validated ingredients. Demand is primarily driven by a growing health-conscious consumer base seeking integrative liver support supplements and a substantial pharmaceutical sector focused on developing combination therapies for liver conditions. The market is highly regulated, with manufacturers requiring strict adherence to cGMP and comprehensive DMF submissions. Most API is sourced from Asia-Pacific producers, but there is a notable trend toward developing novel delivery mechanisms and conducting advanced clinical trials to explore new therapeutic applications beyond traditional hepatoprotection.
Europe
Europe shows a mature and steadily growing market for Magnesium Isoglycyrrhizinate API, influenced by a robust framework for herbal medicinal products under the EMA. There is strong interest from the nutraceutical and functional food sectors, particularly in Western Europe, where liver health supplements are popular. Local manufacturers and formulators place a high premium on quality, traceability, and sustainability of the raw glycyrrhiza supply. Research focuses on confirming efficacy through European clinical standards and exploring co-formulations with other hepatoprotective agents. The market is less about volume production and more about high-value, specialized applications and adherence to stringent regulatory compliance.
South America
The market in South America is an emerging and promising growth area, driven by rising awareness of liver health and an increasing prevalence of lifestyle-related liver disorders. Brazil and Argentina are key markets, with a growing domestic pharmaceutical industry showing interest in local formulation of hepatoprotective drugs. The region benefits from economic partnerships with Asian API suppliers, facilitating imports. However, market development is influenced by economic fluctuations and varying regulatory landscapes across countries. There is potential for growth as healthcare infrastructure improves and regulatory harmonization efforts progress for herbal APIs.
Middle East & Africa
This region is characterized by nascent but expanding demand, primarily fueled by high regional rates of viral hepatitis. The market is largely import-dependent, with sourcing dominated by cost-effective suppliers from the Asia-Pacific. In the Middle East, particularly in the Gulf Cooperation Council countries, there is growing investment in advanced healthcare and a trend toward incorporating evidence-based herbal medicine into formal healthcare systems. Africa presents a long-term opportunity driven by public health initiatives to combat liver disease, though market development is currently constrained by limited local manufacturing capacity and procurement challenges within public health systems.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Cosmetics and skin care manufacturers
API suppliers and distributors
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Magnesium Isoglycyrrhizinate API market was valued at USD 38.2 million in 2025 and is projected to reach USD 58.4 million by 2032, exhibiting a CAGR of 5.3% during the forecast period.
-> Key players include Lianyungang Runzhong Pharmaceutical, Nanjing hongshenghuo Biotechnology, Alikang Pharmaceutical, and Wuhan Weisman Bioengineering, among others.
-> Key growth drivers include rising prevalence of liver diseases, increasing demand for natural and plant-derived APIs, and growth in skincare and dermatological treatments.
-> Asia-Pacific is the dominant market, with China projected to reach USD 22.8 million by 2032, while the U.S. market was valued at USD 6.5 million in 2025.
-> Key product types include Purity98% and Purity<98%. Major applications are in Pharmaceuticals and Cosmetics & Skin Care.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates